Pre-clinical data have demonstrated the anti-tumour effect of the JAK2 inhibitor ruxolitinib in a xenograft model of BIA-ALCL and the JAK/STAT-targeted tyrosine kinase inhibitor sunitinib in vitro [24,41]. Here, SOAT1 is linked to anaplastic large cell lymphoma.